Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.

Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.

Bibliographic Details
Main Authors:	Armitage, J, Collins, R
Format:	Journal article
Language:	English
Published:	2000

Similar Items

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
by: Collins, R, et al.
Published: (2003)

MRC/BHF Heart Protection Study - Reply
by: Collins, R, et al.
Published: (2002)

The MRC/BHF Heart Protection Study: preliminary results.
by: Collins, R, et al.
Published: (2002)

Comments on the MRC/BHF Heart Protection Study - Authors' reply
by: Collins, R, et al.
Published: (2003)

MRC/BHF Heart Protection Study.
by: Vaughan, C, et al.
Published: (2002)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
by: Heart Protection Study Collaborative Group
Published: (2002)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
by: Parish, S, et al.
Published: (2012)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
by: Collins, R, et al.
Published: (2002)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
by: Emberson, J, et al.
Published: (2005)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
by: Bulbulia, R, et al.
Published: (2007)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
by: Emberson, JR, et al.
Published: (2007)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
by: Emberson, J, et al.
Published: (2005)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
by: Bulbulia, R, et al.
Published: (2011)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
by: Collins, R, et al.
Published: (2004)

Randomized trial of cholesterol-lowering and antioxidant vitamins in 7,000 high-risk individuals with LDL cholesterol below 120 mg/dl
by: Collins, R, et al.
Published: (2002)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
by: Baigent, C, et al.
Published: (2011)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
by: Baigent, C, et al.
Published: (2011)

LDL cholesterol targets--how low to go?
by: Bulbulia, R, et al.
Published: (2012)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
by: Safi U. Khan, et al.
Published: (2020-03-01)

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
by: Armitage, J, et al.
Published: (2010)

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group.
by: Wardle, J, et al.
Published: (1996)

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration
by: Wardle, J, et al.
Published: (1996)

Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"
by: Linton MacRae F, et al.
Published: (2001-01-01)

Effects of lowering LDL cholesterol on progression of kidney disease.
by: Haynes, R, et al.
Published: (2014)

Modified methylenedioxyphenol analogs lower LDL cholesterol through induction of LDL receptor expression
by: Zhekang Ying, et al.
Published: (2012-05-01)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
by: Mihaylova, B, et al.
Published: (2019)

The role of statins in clinical medicine -LDL - cholesterol lowering and beyond
by: Swiss Medical Weekly
Published: (2006-01-01)

New and emerging lipid-modifying drugs to lower LDL cholesterol
by: Constantine E Kosmas, et al.
Published: (2021-10-01)

Randomized trial of cholesterol-lowering, and of antioxidant vitamins, in 6,000 people with diabetes mellitus
by: Collins, R, et al.
Published: (2002)

Is it need a criterion LDL cholesterol in definition of metabolic syndrome?
by: Yu. P. Nikitin, et al.
Published: (2014-03-01)

Assessing the impact sensitivity of explosives using the BHF-12A equipment
by: Rădeanu Cristian, et al.
Published: (2020-01-01)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
by: Baigent, C, et al.
Published: (2010)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
by: Storey, B, et al.
Published: (2017)

Short-term LDL cholesterol-lowering efficacy of plant stanol esters
by: Sarkkinen Essi, et al.
Published: (2002-08-01)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
by: Mihaylova, B, et al.
Published: (2012)

Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation
by: Claire Cannet, et al.
Published: (2020-02-01)

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
by: Emberson, J, et al.
Published: (2012)

Different cellular traffic of LDL-cholesterol and acetylated LDL-cholesterol leads to distinct reverse cholesterol transport pathwayss⃞
by: Ming-Dong Wang, et al.
Published: (2007-03-01)

Levels of LDL-cholesterol, Triglyceride and Urate in Patients With Type 2 Diabetes Mellitus
by: Dunja Šojat, et al.
Published: (2020-04-01)

High-risk elderly patients PROSPER from cholesterol-lowering therapy.
by: Collins, R, et al.
Published: (2002)